Danish Investigations of Arrhythmia & Mortality on Dofetilide (Tykosyn®) in Congestive Heart Failure. A trial evaluating the use of dofetilide (Tikosyn) in patients with congestive heart failure and left ventricular dysfunction
Conclusion Dofetilide-treated patients had a 25% lower risk of death than placebo patients
Mentioned in ?
References in periodicals archive ?
The DIAMOND CHF results for dofetilide demonstrate a significant advance in a disease area where patient needs are great, few tolerable medications currently exist and overall disease costs are rapidly increasing.
Presented Tuesday at the European Society of Cardiology meeting, the DIAMOND CHF results were in dramatic contrast to several previous trials with other cardiac arrhythmia agents which showed increased mortality rates compared with placebo, Pfizer said.